Sign inCreate account

Report workspace tools

NCT00645879COMPLETEDanonymous

Safety & Efficacy of Investigational Products: Ornithine Alpha-ketoglutarate, Glutamine, or Disodium Citrate on Hyperammonemia in Propionic Acidemia.

Sponsor

Source record

Nicola Longo

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

ornithine alpha ketoglutarate, glutamine, disodium citrate

Indication / condition

AI-normalized

Propionic Acidemia

Intervention

Source record

ornithine alpha ketoglutarate, glutamine, disodium citrate

Source & freshness

Source record

NCT ID

NCT00645879

Original source

ClinicalTrials.gov

Source last updated

Jan 21, 2015

Ingested at

Jun 07, 2026

Internal sync

Jun 07, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00645879

Title

Safety & Efficacy of Investigational Products: Ornithine Alpha-ketoglutarate, Glutamine, or Disodium Citrate on Hyperammonemia in Propionic Acidemia.

Sponsor

Nicola Longo

Status

COMPLETED

Phase

PHASE1

Condition raw

Propionic Acidemia

Condition normalized

Propionic Acidemia

Modality raw

small molecule

Modality normalized

small molecule

Target raw

ornithine alpha ketoglutarate, glutamine, disodium citrate

Target normalized

ornithine alpha ketoglutarate, glutamine, disodium citrate

Interventions

ornithine alpha ketoglutarate, glutamine, disodium citrate

Public preview

Source record

The objective of this project is to define whether nutritional supplements (ornithine alpha-ketoglutarate, glutamine, or citrate) capable of filling-up the citric acid cycle (anaplerotic therapy) can improve hyperammonemia, glutamine levels, and outcome in patients with propionic acidemia. Ornithine alpha-ketoglutarate, glutamine, and citrate are commonly used as nutritional supplements specially by athletes to increase muscle strength. They can be mixed with formula or other foods.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Safety & Efficacy of Investigational Products: Ornithine Alpha-ketoglutarate, Glutamine, or Disodium Citrate on Hyperammonemia in Propionic Acidemia.

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00645879

Status

COMPLETED

Phase

PHASE1

Sponsor

Nicola Longo

Executive brief

Investment-Ready Snapshot

The objective of this project is to define whether nutritional supplements (ornithine alpha-ketoglutarate, glutamine, or citrate) capable of filling-up the citric acid cycle (anaplerotic therapy) can improve hyperammonemia, glutamine levels, and outcome in patients with propionic acidemia. Ornithine alpha-ketoglutarate, glutamine, and citrate are commonly used as nutritional supplements specially by athletes to increase muscle strength. They can be mixed with formula or other foods.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 21, 2015
Internal syncJun 07, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00645879

Indication

Propionic Acidemia

Modality

small molecule

Target

ornithine alpha ketoglutarate, glutamine, disodium citrate

Intervention

ornithine alpha ketoglutarate, glutamine, disodium citrate

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.